Company profile
Praxis Precision Medicines, Inc.
NASDAQ: PRAX · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
61CFH 66DQ 52GM —SS 64
v0.1 · 55/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ revenue growth (YoY), disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$303.3M
Employees
168
as of 2026-08-06
Market cap
$8.9B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$303.3M-$303.3M2025
Operating income-$326.2M-$326.2M2025
Total assets$937.9M$937.9M2025
Liabilities$59.8M$59.8M2025
Equity$878.1M$878.1M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
License77%
Upfront Payment23%
By geography
Not disclosed.
The read
What is Praxis Precision Medicines, Inc.’s revenue?
Praxis Precision Medicines, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Revolution Medicines, Inc.52DSummit Therapeutics Inc.49DSpyre Therapeutics, Inc.64COruka Therapeutics, Inc.66BScholar Rock Holding Corporation39DDenali Therapeutics Inc.52DNeighbors
Suffolk →Key facts
CEOMarcio Silva De'Souza
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: PRAX
Employees168
IPO date2020-10-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.